Clinical trials: Positron-Emission Tomography
SPECT-CT
Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Prospective Double-Scanning Study
The goal of this study is to collect image data for the StarGuide GX Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) System in a clinical setting.
- Trial name
- NCT07725237
- Testing
- StarGuide GX SPECT/CT Scan
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Frail Elderly
Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults
The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment.
- Trial name
- COGFRAIL (NCT03129269)
- Testing
- MRI and PET scan
- Where
- France
- Volunteers
- 344 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Trial name
- PROFLu (NCT06460454)
- Testing
- PET scan of 18F-FDG
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Malignant Glioma
FMISO-PET in Brain Tumors and SCS Effect
The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients.
- Trial name
- FMISOPETSCS (NCT01868906)
- Testing
- 18F-FMISO, PET without SCS, SCS
- Where
- 2 sites in Spain
- Volunteers
- 6 people
- Sponsor
- Bernardino Clavo, MD, PhD
Breast Cancer Invasive
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
This study aims to explore the diagnostic performance of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node…
- Trial name
- NCT06695039
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Asan Medical Center
Heart Transplant Recipients
The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.
Objective: To assess the relationship between coronary allograft vasculopathy (CAV) and graft function, and to evaluate non-invasive methods for CAV diagnosis.
- Trial name
- NCT02077764
- Testing
- OCT and coronary angiography, Right heart cat., PET
- Where
- Denmark
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital Skejby
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer
This clinical trial studies carbon-11 acetate and fluorine F 18 sodium fluoride positron emission tomography (PET) as a biomarker of treatment response in patients with prostate cancer that does not respond to treatment with…
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02169063
- Testing
- carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography
- Where
- United States
- Sponsor
- University of Washington
Unspecified Adult Solid Tumor, Protocol Specific
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's response to treatment. PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing changes in tumor blood…
- Trial name
- NCT00019565
- Testing
- magnetic resonance imaging, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features…
- Trial name
- NCT05259709
- Testing
- 89Zr˗DFO˗REGN5054, cemiplimab
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Regeneron Pharmaceuticals
HIV Infections
HIV Fat Redistribution and the Evaluation of Brown Fat
The specific aims of this study are to determine whether HIV-infected patients with significant fat redistribution and ectopic fat accumulation have increased brown adipose tissue using 18F-FDG Positron Emission Tomography…
- Trial name
- NCT01098045
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
- Trial name
- NCT03803475
- Testing
- Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
- Where
- United States
- Volunteers
- 485 people
- Sponsor
- Thomas Hope
Prostate Cancer Recurrent, Prostate Cancer
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
- Trial name
- SHAPE-PSMA (NCT06508567)
- Testing
- High Dose Rate Brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Alzheimer's Disease
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease…
- Trial name
- NCT00499200
- Testing
- SRA-444
- Where
- Sweden
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neurological Pathology, Healthy Subjects
[18F]-F13640 as a New Brain Radiopharmaceutical
This clinical assay is designed to validate that [18F]F13640 as a radiotracer of 5-HT1A functional receptors. A first group of healthy subjects underwent a PET scan with arterial blood sampling to determine the kinetic model of…
- Trial name
- F13640 (NCT03347331)
- Testing
- [18F]F13640
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Primary Aldosteronism
Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism
PentixaFor radiolabeled with 68Gallium (68Ga) is a radiopharmaceutical targeting the CXC chemokine receptor 4 (CXCR4) receptor. The CXCR4 receptor is expressed in zona glomerulosa of the adrenal cortex and in aldosterone…
- Trial name
- PENTALON (NCT06478875)
- Testing
- [68Ga]Ga-PentixaFor PET imaging
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study
The purpose of this study is to find out whether short term treatment with a antihypertensive medication prazosin, can influence the levels of a dopamine in the brain.
- Trial name
- NCT01999530
- Testing
- Prazosin Hydrochloride
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
High-grade Glioma, Astrocytoma
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
18F-Fluorothymidine is a recently developed PET tracer to image tumor cell proliferation. Very few data report an interest of using such a tracer for cerebral malignant tumor management.
- Conditions
- High-grade Glioma, Astrocytoma, Glioblastoma
- Trial name
- GLIO-TEP (NCT00624728)
- Testing
- 18F Fluorothymidine PET CT
- Where
- 2 sites in France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Bordeaux
Anxiety Disorder, Major Depressive Disorder
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX
Objective: Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between…
- Trial name
- NCT02230592
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
HER2-positive Breast Cancer
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.
This is an exploratory, prospective and multicentric study aiming to highlight by FES-PET imaging that an anti-HER2 treatment by trastuzumab + pertuzumab can reverse the ERα status in patients with metastatic breast cancer HER2 +…
- Trial name
- REVER (NCT03619044)
- Testing
- 2 FES-PET Imaging will be performed:
- Where
- 6 sites in France
- Volunteers
- 4 people
- Sponsor
- Institut Claudius Regaud
Bone Metastases From Breast or Prostate Cancer
18F-NaF PET Imaging for Bone Scintigraphy
The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
- Trial name
- NCT01930812
- Testing
- NaF PET/CT Imaging, 99mTc-medronate whole body bone scan with SPECT, 18F-Sodium Fluoride (NaF)
- Where
- 10 sites in Canada
- Volunteers
- 286 people
- Sponsor
- British Columbia Cancer Agency
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.